2019

/Tag:2019

Oramed to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place [...]

2019-02-06T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed Initiates Phase I Oral GLP-1 Study Under IND

JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 [...]

2019-01-22T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals’ CEO Letter to Shareholders

JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our partners HTIT, thereby increasing our total payments from HTIT received [...]

2019-01-15T08:55:00+00:00 Categories: Press Releases|Tags: |

Oramed Receives Additional $3 Million Milestone Payment from HTIT

Totaling $33 M in payments from HTIT received to date JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of [...]

2019-01-09T08:40:00+00:00 Categories: Press Releases|Tags: |